Invex Therapeutics Ltd has released a press release.
Invex Receives Written Response from FDA on Type C Meeting
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Story so far
Earlier from Invex Therapeutics
- Invex Granted Type C Meeting with FDA
- Appendix 4C - quarterly
- Invex Successfully Concludes Protocol Assistance with EMA
- Chairmans Address to Shareholders and Presentation
- Investor Presentation
Later from Invex Therapeutics
- Invex Granted Key European Patent for Exenatide
- Appendix 4E and Annual Report
- Exclusive Collaboration and Manufacturing Agreement
- Notice of Investor Call and Presentation
- Global Phase 3 Trial of Presendin to Launch in Q4 2021
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics